| Ann K Porretto-loehrke, PT, DPT, CHT, COMT | |
|
2323 N Casaloma Dr, Appleton, WI 54913-8284 | |
| (920) 730-8833 | |
| Not Available |
| Full Name | Ann K Porretto-loehrke |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 17 Years |
| Location | 2323 N Casaloma Dr, Appleton, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104876986 | NPI | - | NPPES |
| 40231900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 4843024 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hand To Shoulder Center Of Wisconsin Ltd | 6901884337 | 36 |
News Archive
Individuals who lack the capacity to consent to taking part in clinical trials could be missing out on the opportunity to receive potentially beneficial interventions, shows UK research.
VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.
Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
When a pregnancy ends tragically due to fatal abnormalities of the fetus, it is important to understand the medical reasons behind the event. This evaluation can help predict the risk of reoccurrence in future pregnancies. In the case of fetal akinesia deformation sequence (FADS), the fetus may have been affected by a disrupting injury or unavoidable maldevelopment.
› Verified 6 days ago
| Provider Name | Hand To Shoulder Center Of Wisconsin Ltd |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1760420277 PECOS PAC ID: 6901884337 Enrollment ID: O20040712000584 |
News Archive
Individuals who lack the capacity to consent to taking part in clinical trials could be missing out on the opportunity to receive potentially beneficial interventions, shows UK research.
VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.
Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
When a pregnancy ends tragically due to fatal abnormalities of the fetus, it is important to understand the medical reasons behind the event. This evaluation can help predict the risk of reoccurrence in future pregnancies. In the case of fetal akinesia deformation sequence (FADS), the fetus may have been affected by a disrupting injury or unavoidable maldevelopment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ann K Porretto-loehrke, PT, DPT, CHT, COMT 2323 N Casaloma Dr, Appleton, WI 54913-8284 Ph: (920) 730-8833 | Ann K Porretto-loehrke, PT, DPT, CHT, COMT 2323 N Casaloma Dr, Appleton, WI 54913-8284 Ph: (920) 730-8833 |
News Archive
Individuals who lack the capacity to consent to taking part in clinical trials could be missing out on the opportunity to receive potentially beneficial interventions, shows UK research.
VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.
Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.
This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.
When a pregnancy ends tragically due to fatal abnormalities of the fetus, it is important to understand the medical reasons behind the event. This evaluation can help predict the risk of reoccurrence in future pregnancies. In the case of fetal akinesia deformation sequence (FADS), the fetus may have been affected by a disrupting injury or unavoidable maldevelopment.
› Verified 6 days ago
Orthopedic & Spine Therapy Of Menasha Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4000 N Providence Ave, Appleton, WI 54913 Phone: 920-257-2000 | |
Ms. Jennifer Lynn Nevinski, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: N496 Milky Way, Appleton, WI 54915 Phone: 920-738-2960 | |
Chandler Riem, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2105 N Enterprise Ave, Appleton, WI 54913 Phone: 920-560-1000 | |
Kathleen M. Vandrunen, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2915 N Meade St, Appleton, WI 54911 Phone: 920-831-8711 | |
Mrs. Lisa Katherine Buehler, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3375 W Brewster St, Appleton, WI 54914 Phone: 920-749-5870 | |
David Michael Denell, MPT LAT/C Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1818 N Meade St, Appleton, WI 54911 Phone: 920-731-4101 | |
Richelle Ag Fenter, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2200 S Kensington Drive, Appleton, WI 54915 Phone: 920-738-0200 Fax: 920-738-0383 |